The Manila Times17h
Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia
Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström ...
PMLive16h
Roche to launch new innovation centre at Harvard’s Enterprise Research Campus
Roche has announced the launch of a new cardiovascular, renal and metabolism (CVRM) hub at Harvard’s Enterprise Research ...
The Manila Times21h
Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with overweight or obesity
In November 2024, Zealand Pharma presented detailed results from the Phase 1b 16-week multiple ascending dose (MAD) trial at ...
American Association of Individual Investors6h
Which Is a Better Investment, Recursion Pharmaceuticals, Inc. or Zai Lab Limited Stock?
Learn more about whether Recursion Pharmaceuticals, Inc. or Zai Lab Limited is a better investment based on AAII's A+ ...
PharmiWeb18h
Eneboparatide met primary endpoint of normalising…
High-level results from the CALYPSO Phase III trial showed that eneboparatide (AZP-3601), an investigational parathyroid hormone (PTH) receptor 1 agonist, met its primary endpoint with statistical ...
News-Medical.Net on MSN5h
Discovery of new protein could revolutionize cancer drug delivery
A previously unknown protein in a family of bacteria found in soil and the human gut microbiome has been discovered – which could help drug delivery in cancer treatment.
Newly identified bacterial protein helps design cancer drug delivery system
A previously unknown protein in a family of bacteria found in soil and the human gut microbiome has been discovered—which ...
BioPharma Dive15h
How biotech and pharma teams are reaching LPI ahead of schedule
With the right strategy, reaching LPI ahead of schedule isn’t a myth. Learn how some biotech and pharma teams are achieving ...